

Laney K. Jones, PharmD, MPH, CLS, FNLA

180 W Woodhaven Dr • White Haven, PA 18661 • 908-331-1566 • ljones979@gmail.com



EMPLOYMENT

- 2022- Associate Professor, Department of Genomic Health, Geisinger, Danville, PA
- 2018-2022 Assistant Professor, Department of Genomic Health, Geisinger, Danville, PA
- 2017-2022 Assistant Professor, Center for Pharmacy Innovation and Outcomes, Geisinger, Danville, PA
- 2020-2021 Temporary Vaccine Immunizer, Rite Aid, Camp Hill, PA

EDUCATION

Clinical Lipid Specialist	Accreditation Council for Clinical Lipidology	Dec 2021
Postdoc. Fellowship	Center for Pharmacy Innovation and Outcomes Geisinger, Danville, PA	2015-2017
Graduate	Certificate in Implementation Science University of California San Francisco, San Francisco, CA	July 2020
	Master of Public Health Mailman School of Public Health Columbia University, New York, NY	October 2015
	Doctor of Pharmacy Philadelphia College of Pharmacy University of the Sciences, Philadelphia, PA	May 2014
Undergraduate	Bachelor of Science of Pharmaceutical and Healthcare Studies University of the Sciences, Philadelphia, PA	May 2012

HONORS AND AWARDS

- 2022 Chapter President's Service Award, Northeast Chapter of the National Lipid Association
- 2018 Innovation in Pharmacy Practice Literature Award, American Society of Health-System Pharmacists Foundation
- 2018 Honorable Mention Young Investigator Awards Competition, American College of Cardiology
- 2016 Hunninghake Familial Hypercholesterolemia Abstract Award Recipient, Foundation of the National Lipid Association
- 2016 Early Career Investigator Award Recipient, Health Care Systems Research Network

PROFESSIONAL LICENSURE

- Pennsylvania Pharmacist Licensure License Number: RP448854
Issued: 07/11/2014, Expires: 09/30/2024
- Pennsylvania Authorization to Administer Injectables License Number: RPI008740

Issued: 07/11/2014, Expires: 09/30/2024

- Alaska Pharmacist Licensure

License Number: PHAP2329

Issued: 05/29/2015, Expires: 09/30/2024

HEALTH SYSTEM SERVICE

- 2022 - Member, NIH Data Management and Sharing Task Force at Geisinger
- 2021 - Member, Implementation and Evaluation Committee at Geisinger
- 2020 - Co-founder of the Dissemination and Implementation Science Community (DISCO) at Geisinger
- 2021 - Implementation lead for system initiative called ConnectedCare365

PROFESSIONAL ORGANIZATIONS AND SERVICE

- 2022 - Member, Diversity, Inclusion and Equity Task Force, National Lipid Association
- 2022-2023 Treasurer, Northeast Chapter of the National Lipid Association
- 2021-2022 Secretary, Northeast Chapter of the National Lipid Association
- 2020 - Co-Chair, Health Quality & Research Committee, National Lipid Association
- 2020 - Member, Scientific Statements Committee, National Lipid Association
- 2019 - Member, Research Advisory Council, American Society of Health-System Pharmacists Foundation
- 2019 - Panel Reviewer for Innovation in Pharmacy Practice Award, American Society of Health-System Pharmacists
- 2018-2019 Member, Cholesterol Guidelines Dissemination Task Force, National Lipid Association
- 2018 - Board Member, Institute for Human Resources & Services, Inc.
- 2018 - Member, Publication Committee, National Lipid Association
- 2018-2021 At-Large Board Member, Northeast Chapter of the National Lipid Association
- 2018-2020 Member, Society for Implementation Research Collaboration
- 2016 - Member, National Lipid Association
- 2010 - Member, American Society of Health-System Pharmacists

RESEARCH SUPPORT

Active

11/08/2022 – 11/08/2025

\$25,000

Duke Clinical Research Institute

Title: Cardiovascular Multicenter Observational Investigation of Lipid Care in the United States-2 (cvMOBIUS2)

Principal Investigators: Ann Marie Navar and Eric Peterson

Role: Co-Investigator

11/01/2022 – 04/30/2024 R-2305-06052

\$701,056

The Leona M and Harry B Helmsley Charitable Trust

Title: Study of pre-implementation outcomes required to implement preventive screening at well-child visits

Principal Investigator: Laney K Jones

07/01/2021 – 06/30/2026

W81XWH-21-1-0645

\$6,000

Department of Defense

Title: Familial Hypercholesterolemia in the United States: Evaluating a Centralized Cascade Screening Model to Improve Early Diagnosis

Principal Investigator: Zahid Ahmed

Role: Consultant

07/01/2022 – 06/30/2023 SAP# 4100090487 \$259,800

Pennsylvania Department of Health

Title: Transition clinic for youth at-risk for hereditary cancer: pre-implementation study

Principal Investigator: Gemme Campbell-Salome

Role: Co-Investigator, Lead Implementation Scientist

07/01/2022 – 06/30/2026 R01HL159182 \$4,115,890

National Heart Lung and Blood Institute (NHLBI)

Title: Improving Risk Stratification in Familial Hypercholesterolemia (RISK-FH)

Principal Investigator: Matthew Oetjens

Role: Co-Investigator, Lead of Implementation Science Aim

06/01/2022 – TBD

Family Heart Foundation

Title: FH CASCADE Registry

Principle Investigator: Laney K Jones

03/10/2022 – 02/28/2026 R01HG012262 \$1,625,335

National Human Genome Research Institute (NHGRI)

Title: Rational Integration of Polygenic Risk Scores (RIPS)

Principal Investigator: Joseph F Peterson, Jing Hao, David L Veenstra

Role: Co-Investigator

02/01/2022 – 01/31/2023 R61HL161775 \$3,340,482

National Heart Lung and Blood Institute (NHLBI)

Title: Collaborative Approach to Reach Everyone with Familial Hypercholesterolemia: CARE-FH

Multi-Principal Investigator: Laney K Jones and Samuel S Gidding

01/01/2022 – 12/31/2024 \$59,000

National Lipid Association

Title: Translating Evidence based Approaches into optimal Care of High risk ASCVD patients in the U.S. health system (TEACH-ASCVD)

Principal Investigator: Laney K Jones

08/01/2019 – 07/31/2023 R01HL148246 \$2,137,188

National Heart Lung and Blood Institute (NHLBI)

Title: Identification Methods, Patient Activation, and Cascade Testing for FH: IMPACT-FH

Principal Investigator: Laney K Jones

Completed

08/01/2017 – 07/31/2021 R01HG009694

National Human Genome Research Institute (NHGRI)

Title: Rational Integration of clinical SEquencing (RISE)

Principal Investigator: Joseph F Peterson, Jing Hao, David L Veenstra

Role: Co-Investigator

07/01/2020 – 06/30/2021 Geisinger Health Plan

Geisinger Health Plan

Title: Improving Medication reconciliation PProcesses through ObserVation and Evaluation: IMPROVE
Principle Investigator: Laney K. Jones

07/01/2018 – 06/30/2020 K12HL137942

National Heart Lung and Blood Institute (NHLBI)

Title: Washington University K12 Program in T4 Implementation Research

Principal Investigator: Victor Davila-Roman

Role: Scholar

10/26/2018 – 10/25/2019 Amgen

Amgen

Title: Therapeutic Intensity of Lipid Lowering Therapy in Response to Recurrent Cardiovascular Events

Principal Investigator: Kristen Tecson, Peter McCullough

Role: Co-Investigator

01/01/2016 – 06/30/2019 SAP# 4100072547

Pennsylvania Department of Health – PA CURE

Title: Evaluation of System-Wide Medication Prior Authorization Process

Principal Investigator: Michael A. Evans

Role: Co-Investigator

PROFESSIONAL PUBLICATIONS

Peer-Reviewed Publication

1. Schubert TJ, Clegg K, Karalis D, Desai NR, Marrs JC, McNeal C, Mintz GL, Romagnoli KM, **Jones LK**. Impact of telehealth on the current and future practice of lipidology: a scoping review. *J Clin Lipidol*. ACCEPTED
2. Dikilitas O, Sherafati A, Saadatagah S, Satterfield BA, Kochan DC, Anderson KC, Chung WK, Hebring SJ, Salvati ZM, Sharp RR, Sturm AC, Gibbs RA, Rowley R, Venner E, Linder JE, **Jones LK**, Perez EF, Peterson JF, Jarvik GP, Rehm HL, Zouk H, Roden DM, Williams MS, Manolio TA, Kullo IJ. Familial hypercholesterolemia in the eMERGE network: prevalence, penetrance, cardiovascular risk, and outcomes after return of results. *Circ Genom Precis Med*. ACCEPTED
3. Agarwala A, Deych E, **Jones LK**, Sturm AC, Aspary K, Ahmad Z, Ballantyne CM, Goldberg AC. Sex-related differences in premature cardiovascular disease in familial hypercholesterolemia. *J Clin Lipidol*. 2022;S1933-2874(22)00327-0. PMID: [36470719](#)
4. Warden BA, Guyton JR, Kovacs AH, Durham JA, **Jones LK**, Dixon DL, Jacobson TA, Duell PB. Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association. *J Clin Lipidol*. 2022;S1933-2874(22)00245-8. PMID: [36115813](#)
5. Baker A, Tolwinski K, Atondo J, Davis FD, Goehringer J, **Jones LK**, Piszczko CJ, Sturm AC, Williams JL, Williams MS, Rahm AK, Buchanan AH. Understanding the patient experience of receiving clinically actionable genetic results from the MyCode Community Health Initiative, a population-based genomic screening initiative. *J Pers Med*. 2022.12(9). PubMed PMID: 36143296 PMCID: [PMC9501087](#) *Special Issue Precision Medicine in Clinical Practice
6. Spencer SJ, **Jones LK**, Guzauskas GF, Hao J, Williams MS, Peterson JF, Veenstra DL. Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States. *J Clin Lipidol*. 2022;16(5):667-675. PMID: 35961838
7. **Jones LK**, Sturm AC, Gionfriddo MR. Translating guidelines into practice via implementation science: An update in lipidology. *Curr Opin Lipidol*. 2022;33(6):336-341. PMID: 35779062 PMCID: [PMC9640274](#)
*Invited review

8. **Jones LK**, Chen N, Hassen D, McMinn M, Klinger T, Hartzel DN, Veenstra D, Spencer S, Snyder SR, Peterson JF, Schlieder V, Sturm AC, Gidding SS, Williams MS, Hao J. Impact of a population genomic screening program on health behaviors related to familial hypercholesterolemia risk reduction. *Circ Genom Precis Med.* 2022;15(5):e003549. PMID: 35862023 PMCID: [PMC9584046](#)
9. **Jones LK**, Strande NT, Calvo EM, Chen J, Rodriguez G, McCormick CZ, Hallquist MLG, Savatt JM, Rocha H, Williams M, Sturm AC, Buchanan A, Glasgow RE, Martin CL, Rahm AK. A RE-AIM framework analysis of DNA-based population screening: using implementation science to translate research into practice in a healthcare system. *Front Genet.* 2022;13:883073. PMID: 35692820 PMCID: [PMC9174580](#) *Research Topic: DNA-based Population Screening for Precision Public Health
10. **Jones LK**, Walters N, Brangan A, Ahmed CD, Wilemon KA, Campbell-Salome G, Rahm AK, Gidding SS, Sturm AC. Patient experiences align with the familial hypercholesterolemia global call to action. *Am J Prev Cardiol.* 2022;10:100344. PMID: 35517872 PMCID: [PMC9061613](#)
11. Tecson KM, Kluger AY, Cassidy-Bushrow AE, Liu B, Coleman CM, **Jones LK**, Jefferson CR, VanWormer JJ, McCullough PA. Usefulness of statins as secondary prevention against recurrent and terminal major adverse cardiovascular events. *Am J Cardiol.* 2022;176:37-42. PMID: [35606173](#)
12. **Jones LK**, Williams MS, Ladd IG, Cawley D, Ge S, Hao J, Hassen D, Hu Y, Kirchner HL, Kobylinski M, Lesko MG, Nelson MC, Rahm AK, Rolston DD, Romagnoli KM, Schubert TJ, Shuey TC, Sturm AC, Gidding SS. Collaborative Approach to Reach Everyone with Familial Hypercholesterolemia: CARE-FH Protocol. *J Pers Med.* 2022;12(4). PMID: 35455722 PMCID: [PMC9024715](#) *Special Issue Personalized Medicine: The Future of Health Care
13. Andrick B, Tusing L, **Jones LK**, Hu Y, Sneidman R, Gregor C, Basu S, Lynch JP, Vadakara J. The impact of a hematopoietic cellular therapy pharmacist on clinical and humanistic outcomes: A RE-AIM framework analysis. *Transplant Cell Ther.* 2022;28(6):334.e9. PMID: [35189400](#)
14. **Jones LK**, Brownson RC, Williams MS. Applying implementation science to improve care for familial hypercholesterolemia. *Curr Opin Endocrinol Diabetes Obes.* 2022;29(2):141-151. PMID: 34839326 PMCID: [PMC8915991](#) *Invited review
15. **Jones LK**, Hayduk V, Romagnoli KM, Flango A, Marks J, Graham J, Gionfriddo MR. Evaluation of an educational strategy to improve medication reconciliation in ambulatory care. *J Am Pharm Assoc.* 2022;62(4):1179-1188.e3. PMID: [35125293](#)
16. **Jones LK***, Sarkies MN*, Gidding SS, Watts GF. Improving clinical practice guidelines with implementation science. *Nat Rev Cardiol.* 2022;19(1):3-4. PMID: [34799708](#) *Invited comment
17. **Jones LK**, Ladd IG, Gregor C, Evans MA, Graham J, Gionfriddo MG. Evaluating implementation outcomes (acceptability, adoption, and feasibility) of two initiative to improve the medication prior authorization process. *BMC Health Serv Res.* 2021;21(1):1259. PMID: 34801025 PMCID: [PMC8606066](#)
18. Agarwala A, Bekele N, Deych E, Rich MW, Hussain A, **Jones LK**, Sturm AC, Aspary K, Nowak E, Ahmad Z, Ballantyne CM, Goldberg AC. Racial disparities in modifiable risk factors and statin usage in black patients with familial hypercholesterolemia. *J Am Heart Assoc.* 2021;10(17):e020890. PMID: [34431361](#) *JAHA Spotlight on Racial and Ethnic Disparities in Cardiovascular Medicine
19. **Jones LK**, Jefferson CR, Chen N, Murray MF. Genetic screening for familial hypercholesterolemia identifies patients not meeting cholesterol treatment guidelines. *Coron Artery Dis.* 2021;32(6):588-589. PMID: [33394692](#)
20. **Jones LK**, Walters N, Brangan A, Ahmed CD, Gatusky M, Campbell-Salome G, Ladd IG, Sheldon A, Gidding SS, McGowan MP, Rahm AK, Sturm AC. Acceptability, appropriateness, and feasibility of

automated screening approaches and family communication methods for identification of familial hypercholesterolemia: stakeholder engagement results from the IMPACT-FH study. *J Pers Med*. 2021;11(6). PMID: 34205662 PMCID: [PMC8234213](#) *Special Issue Genomic Medicine for Cardiovascular Disease

21. **Jones LK**, Tilberry S, Gregor C, Yaeger LH, Hu Y, Sturm AC, Seaton TL, Waltz TJ, Rahm AK, Goldberg A, Brownson RC, Gidding SS, Williams MS, Gionfriddo MR. Implementation strategies to improve statin utilization in individuals with hypercholesterolemia: a systematic review and meta-analysis. *Implement Sci*. 2021;16(1):40. PMID: 33849601 PMCID: [PMC8045284](#)
22. **Jones LK**, McMinn M, Kann D, Lesko M, Sturm AC, Walters N, Chen N, Fry K, Brownson RC, Gidding SS, Williams MS, Rahm AK. Evaluation of a multidisciplinary lipid clinic to improve the care of individuals with severe lipid conditions: a RE-AIM Framework Analysis. *Implement Sci Commun*. 2021;2(1):32. PMID: 33740154 PMCID: [PMC7977494](#)
23. Campbell-Salome G, **Jones LK**, Masnick M, Walton N, Ahmed C, Buchanan A, Brangan A, Esplin E, Kann D, Ladd I, Kelly M, Kindt I, Kirchner H, McGowan M, Morales A, Myers K, Oetjens M, Rahm AK, Schmidlen T, Sheldon A, Simmons E, Snir M, Strande N, Walters N, Wilemon K, Williams M, Gidding S, Sturm A. Developing and optimizing innovative tools to address familial hypercholesterolemia underdiagnosis: Identification Methods, Patient Activation, and Cascade Testing for Familial Hypercholesterolemia (IMPACT-FH). *Circ Genom Precis Med*. 2021;14(1):e003120. PMID: 33480803 PMCID: [PMC7892261](#).
24. **Jones LK**, Sturm AC, Seaton TL, Gregor C, Gidding SS, Williams MS, Rahm AK. Barriers, facilitators, and solutions to familial hypercholesterolemia treatment. *PLoS One*. 2020;15(12):e0244193. eCollection 2020. PMID: 33362269 PMCID: [PMC7757879](#). *Primary and Secondary Prevention of Cardiovascular Disease Collection
25. Buchanan AH, Kirchner HL, Schwartz MLB, Kelly MA, Schmidlen T, **Jones LK**, Hallquist MLG, Rocha H, Betts M, Schwiter R, Butry L, Lazzeri AL, Frisbie LR, Rahm AK, Hao J, Willard HF, Martin CL, Ledbetter DH, Williams MS, Sturm AC. Clinical outcomes of a genomic screening program for actionable genetic conditions. *Genet Med*. 2020;22(11):1874-1882. PMCID: [PMC7605431](#)
26. **Jones LK**, Ladd IG, Gionfriddo MR, Gregor C, Evans MA, Graham J. Medications requiring prior authorization across health insurance plans. *Am J Health Syst Pharm*. 2020;77(8):644-648. PMID: [32123921](#)
27. **Jones LK**, Gidding SS, Seaton TL, Goldberg A, Gregor C, Sturm AC, Brownson RC, Rahm, AK, Williams MS. Developing implementation strategies to improve uptake of guideline-recommended treatments for individuals with familial hypercholesterolemia: a protocol. *Res Social Adm Pharm*. 2020;16(3):390-395. PMID: [31229402](#)
28. Patel P, Hu Y, Kolinovsky A, Geng Z, Ruhl J, Krishnamurthy S, deRichemond C, Khan A, Kirchner HL, Metpally R, **Jones LK**, Sturm AC, Carey D, Snyder S, Williams MS, Mehra VC. Hidden burden of electronic record-identified familial hypercholesterolemia: clinical outcomes and cost of medical care. *J Am Heart Assoc*. 2019;8(13):e011822. PMID: [31256702](#)
29. Robinson JG, Jayanna MB, Brown AS, Aspary K, Orringer C, Gill EA, Goldberg A, **Jones LK**, Maki K, Dixon DL, Saseen J, Soffer D. Enhance the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. *J Clin Lipidol*. 2019;13(4):525-537. PMID: [31281070](#)
30. **Jones LK**, Lussier ME, Brar J, Byrne MC, Durham M, Kiokemeister F, Kjaer K, Le H, Magee C, McKnight E, Mehta N, Papp J, Pastwa E, Radovich P, Ravin K, Ruther M, Woodie G, Wrona S,

- Yousefvand G, Greskovic G. Current interventions to promote safe and appropriate pain management. *Am J Health Syst Pharm*. 2019;76(11):829-834. PMID: [31415689](#)
31. **Jones LK**, Ladd IG, Gregor C, Evans MA, Graham J, Gionfriddo MR. Understanding the medication prior-authorization process: a case study of patients and clinical staff from a large rural integrated health delivery system. *Am J Health Syst Pharm*. 2019;76(7):453-459. PMID: [31361821](#)
 32. Pendergrass SA, Crist RC, **Jones LK**, Hoch JR, Berrettini WH. The importance of buprenorphine research in the opioid crisis. *Mol Psychiatry*. 2019;24(5):626-632. PMID: [30617273](#)
 33. **Jones LK**, Rahm AK, Manickam K, Butry L, Lazzeri A, Corcoran T, Komar D, Sturm AC, Murray MF. Healthcare Utilization and Patients' Perspectives After Receiving a Positive Genetic Test for Familial Hypercholesterolemia: A Pilot Study. *Circ Genom Precis Med*. 2018;11:e002146. PMID: [30354341](#)
 34. Goehringer, JM, Bonhag MA, **Jones LK**, Schmidlen T, Schwartz M, Rahm AK, Williams JL, Williams MS. 2018 Generation and Implementation of a Patient-Centered and Patient-Facing Genomic Test Report in the EHR. *eGEMs*. 2018;6(1):14,1–10. PMCID: [PMC6078113](#)
 35. Murray MT, Johnson CL, Cohen B, Jackson O, **Jones LK**, Saiman L, Larson EL, Neu N. Use of Antibiotics in Paediatric Long Term Care Facilities. *J Hosp Infect*. 2018; 99(2):139-144. PMCID: [PMC5924588](#)
 36. **Jones LK**, Rahm AK, Gionfriddo MR, Williams JL, Fan A, Pulk RA, Wright EA, Williams MS. Developing pharmacogenomic reports: Insights from patients and clinicians. *Clin Transl Sci*. 2018;11(3):289-295. PMCID: [PMC5944570](#)
 37. **Jones LK**, Pulk RA, Gionfriddo GR, Evans MA, Parry D. Utilizing big data to provide better health at lower cost. *Am J Health Syst Pharm*. 2018;75(7):427-435. PMID: [29572311](#)
 38. Gionfriddo MR, Pulk RA, Sahni DR, Vijayanagar SG, Chronoswki JJ, **Jones LK**, Evans, MA, FeldmanSR, Pride H. ProvenCare-Psoriasis: A disease management model to optimize care. *Dermatol Online J*. 2018; 24(3). PMID: [29634876](#)
 39. **Jones LK**, Greskovic G, Grassi DM, Graham J, Sun H, Gionfriddo MR, Murray MF, Manickam K, Nathanson DC, Wright EA, Evans MA. Medication therapy disease management: Geisinger's approach to population health management. *Am J Health Syst Pharm*. 2017;74(18):1422-1435. PMID: [28887344](#)
*2018 Innovation in Pharmacy Practice Literature Award, American Society of Healthsystem Pharmacy Foundation
 40. Abul-Husn NS, Manickam K, **Jones LK**, Wright EA, Hartzel DN, Gonzaga-Jauregui C, O'Dushlaine C, Leader JB, Lester Kirchner H, Lindbuchler DM, Barr ML, Giovanni MA, Ritchie MD, Overton JD, Reid JG, Metpally RP, Wardeh AH, Borecki IB, Yancopoulos GD, Baras A, Shuldiner AR, Gottesman O, Ledbetter DH, Carey DJ, Dewey FE, Murray MF. Genetic Identification of Familial Hypercholesterolemia within a Single U.S. Health System. *Science*. 2016;354(6319). PMID: [28008010](#)

Complete List of Published Work in My Bibliography:

<https://www.ncbi.nlm.nih.gov/labs/bibliography/1FGdddsc9ly5l/bibliography/public/>

Other Publications

1. Jones LK. NELA Chapter Update. *LipidSpin*. Fall 2022.
2. Jones LK. NELA Chapter Update – A year of virtual gatherings and more plans. *LipidSpin*. Fall 2021.
3. Jones LK, Kann D. Specialty Corner – Application of implementation science to improve uptake of electronic tools. *LipidSpin*. Winter 2020.

Invited Presentations

1. Implementing treatment guidelines. FH Summit. FH Australasia Network. Virtual. October 2022.
2. Implementing Implementation Science: Translating Research to Clinical Practice. American College of Clinical Pharmacy. San Francisco, CA. October 2022.
3. Journey to becoming a Pharmacist Scientist. Thomas Jefferson College of Pharmacy. Philadelphia, PA. October 2022.
4. Journey to becoming a Pharmacist Scientist. Texas Southern University School of Pharmacy Clinical Conference. Virtual. August 2022.
5. Applying implementation science methods to address gaps, develop strategies, and improve health. National Lipid Association Scientific Session. Scottsdale, AZ, June 2022.
6. NHLBI Implementation Science Building Capacity Workshop. Virtual. December 2021.
7. National Lipid Association (NLA) Scientific Sessions Recap. Virtual. November 2021.
8. Using Implementation Science to Improve Hypercholesterolemia Care. 2021 European Society of Medicine (ESMED) Congress. Vienna, Austria and Virtual. November 2021.
9. Highlights on Implementation Science from Identification Methods, Patient Activation, and Cascade Testing for FH: IMPACT-FH Study. 2020 FH Global Summit. Virtual. March 2021.
10. Exploring the Systems of Care in ASCVD Management. National Lipid Association. Virtual. February 2021.
11. Multi-Disciplinary Perspectives in Lipid Management. American Medical Group Association Diabetes Bundle Webinar. December 2019.
12. Where on the Genome are You? Discussing the Clinical and Economic Utility of Whole Genome Sequencing. AMCP Nexus. National Harbor, MD, October 2019.
13. Developing implementation strategies to improve uptake of guideline-recommended treatments for individuals with familial hypercholesterolemia. WUNDIR Meeting. Washington University in St. Louis, MO, May 2019.
14. How Implementation Science Can Help Improve Care for Individuals with Familial Hypercholesterolemia. University of Pennsylvania. Philadelphia, PA, January 2019.
15. Implementation Science Approaches to Improve Patient and Provider Interactions within a Health System. NHLBI FH Workshop. Bethesda, MD, November 2018.
16. How Community-Based Pharmacists Can Partner with Clinicians in Reducing Opioids for Chronic Non-Cancer Pain. RBC Cardinal Health. San Diego, CA, June 2018.
17. Generation Rx – How Pharmacists are at the Center of community Collaboration in Preventing Prescription Drug Misuse. RBC Cardinal Health. San Antonio, TX, July 2017.
18. Medication Therapy Disease Management – Chronic Noncancer Pain Program. American Society of Health-System Pharmacy Foundation Award for Excellence in Medication-Use Safety Webinar. June 2016.
19. Don't Give up Hope! Emerging Approaches to Managing Poorly Controlled Diabetes (CE). Pennsylvania Pharmacists Association Midyear Meeting. Harrisburg, PA, January 2016.

Platform Poster Presentations

1. Berry AS, **Jones L**, Sturm AC, Gidding S, Oetjens MT. Investigation of familial hypercholesterolemia subtypes in the UK Biobank. Presented at the American Heart Association Epidemiology and

Prevention-Lifestyle and Cardiometabolic Health Scientific Sessions. Chicago, IL. March 2022. *The William B Kannel, MD, Memorial Lectureship in Preventive Cardiology and Oral Abstract Presentations on Preventive Cardiology

2. **Jones L**, Rahm AK, Sturm A, Lazzeri A, Butry L, Corcoran T, Manickam K, Murray MF. Responses to receipt of incidental genetic findings for familial hypercholesterolemia in adult biobank participants. *JACC*. 2018;71(11 Supplement):A2671. American College of Cardiology Conference, March 2018, Orlando, FL. *Honorable Mention Young Investigator Awards Competition, American College of Cardiology
3. **Jones L**, Wright E, Hartzel D, Lindbuchler D, Leader J, Kirchner HL, Overton J, Reid J, Evans M, Dewey F, Murray M. Baseline Undertreatment of Adults with Newly Diagnosed Familial Hypercholesterolemia by Genomic Sequencing. National Lipid Association Scientific Sessions. New Orleans, LA, May 2016. *J Clin Lipidol*. 2016;10(3):692-693. *Hunninghake Familial Hypercholesterolemia Abstract Award Recipient, Foundation of the National Lipid Association
4. **Jones LK**, Wright EA, Evans M, Williams MS, Murray MF. An Innovative Patient-centered, Multidisciplinary Approach for the Delivery of Genomic Sequencing Results and Pharmacist-led Lipid Management to Patients with Familial Hypercholesterolemia. Health Care Systems Research Network Annual Meeting. Atlanta, GA, April 2016. *J Patient Cent Res Rev*. 2016;3:194. *Early Career Investigator Award Recipient, Health Care Systems Research Network

Poster Presentations

1. Gidding SS, Kirchner HL, Brangan A, Howard W, Myers KD, Morgan KM, Shuey TC, Staszak D, Strande NT, Walters NL, Yu KD, Wilemon KA, Williams MS, Jones LK, Sturm AC. Yield of a Familial Hypercholesterolemia Genetic Diagnosis After Electronic Health Record and Genomic Data Screening. Presented at American Heart Association Scientific Sessions. Chicago, IL, November 2022.
2. Dikilitas O, Sherafati A, Saadatagah S, Satterfield BA, Kochan DC, Anderson KC, Chung WK, Hebring SJ, Salvati ZM, Sharp RR, Sturm AC, Gibbs RA, Rowley R, Venner E, Linder JE, **Jones LK**, Perez EF, Peterson JF, Jarvik GP, Rehm HL, Zouk H, Roden DM, Williams MS, Manolio TA, Kullo IJ. Familial Hypercholesterolemia in the eMERGE Network: Prevalence, Penetrance, Cardiovascular Risk, and Outcomes after Return of Results. Presented at American Heart Association Scientific Sessions. Chicago, IL, November 2022.
3. **Jones LK**, Duboski V, Romagnoli K, Flango A, Graham J, Gionfriddo MR. Evaluation of an educational strategy to improve medication reconciliation in ambulatory care. Presented at the 14th Annual Conference on the Science of Dissemination and Implementation. Virtual, December 2021.
4. **Jones LK**, Sheldon A, Walters N, Brangan A, Wilemon K, Salome-Campbell G, Rahm AK, Gidding SS, Sturm AC. Familial hypercholesterolemia patient perspectives and their alignment with the FH global call to action. Presented at the American Heart Association Scientific Sessions. Virtual, November 2021.
5. Agarwala A, Deych E, **Jones LK**, Sturm AC, Aspary K, Ahmad Z, Ballantyne CM, Goldberg AC. Sex-related differences in premature cardiovascular disease in individuals with familial hypercholesterolemia. Presented at the American Heart Association Scientific Sessions. Virtual, November 2021.
6. Rahm AK, Chen J, **Jones L**, McCormick C, Buchanan A, Sturm A, Strande N, Martin C. Geisinger precision health programs: creating a learning laboratory to understand implementation, clinical utility, and public health benefit of population-based genomic screening. Presented at the Society of Behavioral Medicine. Virtual, April 2021.

7. Andrick B, Tusing L, **Jones L**, Hu Y, Sneidman R, Lynch J, Basu S, Vadakara J. Hematopoietic cellular therapy pharmacist implementation at a rural transplant center: impact on clinical and humanistic outcomes using the RE-AIM framework. Presented at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. Virtual, February 2021.
8. Gatusky M, Walters N, Brangan A, Ahmed CD, Campbell-Salome G, Sheldon A, McGowan M, Rahm AK, Sturm AC, **Jones LK**. Acceptability, appropriateness and feasibility of novel approaches for identification of familial hypercholesterolemia. Presented at the 13th Annual conference on the Science of Dissemination and Implementation in Health. Virtual, December 2020.
9. Agarwala AP, Deych E, Hussain A, **Jones LK**, Sturm AC, Aspry KE, Ahmad Z, Ballantyne C, Goldberg AC. Cardiovascular risk assessment in patients with diabetes and familial hypercholesterolemia. Presented at the National Lipid Association Annual Meeting. Virtual, December 2020.
10. Agarwala AP, Deych E, Hussain A, **Jones LK**, Sturm AC, Aspry KE, Ahmad Z, Ballantyne C, Goldberg AC. Validation of the Montreal-FH risk score in a United States based cohort of patients with familial hypercholesterolemia. Presented at the National Lipid Association Annual Meeting. Virtual, December 2020.
11. Agarwala AP, Deych E, Hussain A, **Jones LK**, Sturm AC, Aspry KE, Ahmad Z, Ballantyne C, Goldberg AC. Racial disparities and modifiable cardiovascular risk factors in black patients with familial hypercholesterolemia. Presented at the National Lipid Association Annual Meeting. Virtual, December 2020.
12. Tecson KM, Kluger AY, Cassidy-Bushrow AE, Liu B, Coleman CM, **Jones LK**, Jefferson CR, VanWormer JJ, Xiang P, Habib M, Mues KE, McCullough PA. Early Statin Use and Recurrent Major Adverse Cardiovascular Events: A Multicenter Study. Presented at the National Lipid Association Annual Meeting. Virtual, December 2020.
13. Hao J, Chen N, Hassen D, Klinger T, McMinn M, Hartzel DN, Veenstra D, Spencer S, Williams M, Snyder S, Peterson J, Schlieder V, **Jones LK**. Providers Prescribing Behavior for Lipid-lowering Therapy after Receiving Patients Positive Genetic Test for Familial Hypercholesterolemia. Presented at the National Lipid Association Annual Meeting. Virtual, December 2020.
14. **Jones LK**, Chen N, Hassen D, Klinger T, McMinn M, Hartzel DN, Veenstra D, Spencer S, Snyder SR, Peterson JF, Woods LA, Schlieder V, Williams MS, Hao J. Disclosure of a genetic disposition to familial hypercholesterolemia improves adherence to lipid lowering therapy. Presented at the National Lipid Association Annual Meeting. Virtual, December 2020.
15. **Jones LK**, Walters N, Brangan A, Ahmed CD, Campbell-Salome G, Sheldon A, McGowan M, Rahm AK, Sturm AC. Acceptability and feasibility of novel screening models and family communication methods for familial hypercholesterolemia. Presented at the American Heart Association Scientific Sessions. Virtual, November 2020.
16. Agarwala AP, Deych E, Hussain A, **Jones LK**, Sturm AC, Aspry KE, Ahmad Z, Ballantyne C, Goldberg AC. Racial disparities and modifiable cardiovascular risk factors in black patients with familial hypercholesterolemia. Presented at the American Heart Association Scientific Sessions. Virtual, November 2020.
17. Hao J, Chen N, Hassen D, Klinger T, McMinn M, Hartzel DN, Veenstra D, Spencer S, Williams M, Snyder S, Peterson J, Schlieder V, **Jones L**. Providers' Prescribing Behavior for Lipid-lowering Therapy after Receiving Patients' Positive Genetic Test for Familial Hypercholesterolemia. Presented at the 2020 Health Care Systems Research Network Conference. Canceled, April 2020.

18. **Jones LK**, Tilberry S, Frisbie L, Gregor C, Gionfriddo MR, Gidding SS, Waltz T, Seaton TL, Williams MS. Utilization of implementation strategies to improve statin adherence and prescribing and LDL-C reduction in individuals with hypercholesterolemia. Presented at the Dissemination and Implementation Science Meeting. Arlington, VA, December 2019.
19. **Jones LK**, Gionfriddo MR, Tilberry S, Frisbie L, Gregor C, Gidding S, Williams MS, Seaton TL. Implementation strategies to improve statin utilization in individuals with hypercholesterolemia: a systematic review. Presented at the American College of Clinical Pharmacy Annual Meeting. New York, NY, October 2019.
20. Spencer S, Guzauskas G, Williams M, Snyder S, **Jones L**, Hao J, Hassen D, Peterson J, Veenstra D. Cost Effectiveness of Population-Wide Genomic Screening of Familial Hypercholesterolemia: Importance of FH Patient Statin Uptake and Achieving Target LDL Levels. Presented at the 41st Annual Meeting of the Society of Medical Decision Making. Portland, Oregon, October 2019.
21. **Jones LK**, Schlottmann O, Rahm A, Seaton T, Gregor G, Sturm A, Williams M. Uncovering barriers and facilitators to caring for familial hypercholesterolemia. *J Clin Lipidol.* 2019;13(3):e30. Presented at the National Lipid Association 2019 Scientific Sessions. Miami, FL, May 2019.
22. **Jones LK**, Rahm AK, Seaton TL, Gregor C, Sturm AC, Williams MS. Exploring barriers to and facilitators of uptake of evidence-based treatment for familial hypercholesterolemia: patient perspectives. *Journal of Investigative Medicine.* 2019;67(5):867. Presented at the CSCTR 2019 Annual Meeting. Chicago, IL, April 2019.
23. Ladd I, Gregor C, Graham J, Evans M, Gionfriddo M, **Jones L**. Geisinger provider experience with prior authorization. *J Patient Cent Res Rev.* 2019;6:52-126. P14.06 Presented at the 25th annual Health Care Systems Research Network Conference. Portland, Oregon, April 8–10, 2019.
24. Manickam K, Siemon A, **Jones LK**. Misattributed parentage and public health genomics. Presented at the Annual Meeting of the American College of Medical Genomics. Seattle, WA, April 2019.
25. **Jones LK**, Ladd I, Graham J, Evans M, Gionfriddo M. Exploring patient and healthcare professional experience with the medication prior authorization process within a rural healthcare setting. *J Patient Cent Res Rev.* 2018;5:56-131. Presented at the 24th annual Health Care Systems Research Network Conference. Minneapolis, MN, April 2018.
26. Oetjens MT, Leader JB, Sturm AC, **Jones LK**, Martin CL, Ledbetter DH. Common Genetic Variation Contributes to the Variable Expressivity of Monogenic Familial Hypercholesterolemia. Presented at the 68th Annual Meeting of The American Society of Human Genetics. San Diego, CA, 2018.
27. Troiani V, Adamson K, Robishaw S, Krishnamurthy S, Metpally R, **Jones L**, Pendergrass S, Chronowski J, Lam C, Crist R, Doyle G, Ferraro T, Robishaw J, Berrettini W. Clinical and Genetic Risk Factors Associated with Opioid Use Disorder in Patients with Chronic Noncancer Pain. Presented at the National Institute of Drug Abuse. 2018.
28. Pulk RA, Greskovic GA, Bolesta S, **Jones LK**, Gionfriddo MR, Buchanan AH, Sturm AC, Manickam K, Murray MF, Wright E, Williams MS. Clinical pharmacy services for patients with genetically identified disease risk. *Pharmacotherapy.* 2017;37(12):E226. Presented at the American College of Clinical Pharmacy Annual Meeting. Phoenix, AZ, October 2017.
29. **Jones L**, Lazzeri A, Manickam K, Murray M. Early Follow-up for Patients Identified with Familial Hypercholesterolemia Through a Population Genetic Screening Initiative. *J Clin Lipidol.* 2017;11(3):811. Presented at the National Lipid Association Annual Meeting. Las Vegas, NV, May 2017.
30. Pulk R, **Jones L**, Chronowski J, Pride H, Wright E, Evans M. Geisinger's use of clinical carepaths: impact of a psoriasis carepath on process, clinical, and economic outcomes. *J Patient Cent Res Rev.*

2017;4(3):188. Presented at the 23th annual Health Care Systems Research Network Conference. San Diego, CA, April 2017.

31. **Jones LK**, Rahm AK, Williams J, Gionfriddo M, Fan A, Wright E, Williams M. Return of Pharmacogenomic Results: What is Important to Patients and Healthcare Professionals? Presented at the Annual Meeting of the American College of Medical Genomics. Phoenix, AZ, March 2017.
32. **Jones LK**, Graham J, Maeng D, Evans MA, Harris R, Wright EA. Oral antidiabetic medication adherence and glycemic control associated with fewer hospitalizations and emergency department visits. Presented at the Annual Conference of the Health Care Systems Research Network. Atlanta, GA, April 2016.
33. Johnson C*, **Jones LK***, Neu N, Murray M, Saiman L. Antibiotic Use in 3 Pediatric Long-term Care Facilities. Poster presented at the Pediatric Academic Society. Baltimore, MD, April 2016.

MENTORSHIP

Undergraduate Research Students

- 06/2016-07/2016 Kelly Kempa—Mentor

Medical School Research Students

Geisinger Commonwealth School of Medicine, Scranton, PA

- 01/2023-present Alexis Blackburn—Mentor
- 06/2022-present Katarina Clegg—Mentor
- 01/2022-present Tyler Schubert—Mentor and Chair of Research Honors Program
- 06/2021-present Evan Calvo—Mentor
- 06/2021-12/2022 Gabriela Rodriguez—Mentor
- 06/2020-07/2020 Michael Gatusky—Mentor
- 06/2019-03/2020 Stephanie Tilberry—Mentor
- 06/2018-07/2018 Kishan Patel—Mentor
- 06/2018-07/2018 Michelle Stefanelli—Mentor
- 06/2017-07/2017 Timothy Corcoran—Mentor